Summit Trail Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $793K | Buy |
+11,351
| New | +$793K | 0.01% | 558 |
|
|
2024
Q4 | – | Sell |
-7,675
| Closed | -$598K | – | 432 |
|
|
2024
Q3 | $598K | Sell |
7,675
-922
| -11% | -$71.8K | 0.01% | 358 |
|
|
2024
Q2 | $670K | Buy |
8,597
+2,159
| +34% | +$168K | 0.02% | 312 |
|
|
2024
Q1 | $436K | Sell |
6,438
-600
| -9% | -$40.7K | 0.01% | 365 |
|
|
2023
Q4 | $474K | Buy |
7,038
+273
| +4% | +$18.4K | 0.02% | 294 |
|
|
2023
Q3 | $458K | Sell |
6,765
-3,267
| -33% | -$221K | 0.02% | 291 |
|
|
2023
Q2 | $718K | Buy |
10,032
+4,931
| +97% | +$353K | 0.03% | 206 |
|
|
2023
Q1 | $354K | Buy |
+5,101
| New | +$354K | 0.01% | 288 |
|
|
2022
Q2 | – | Sell |
-3,606
| Closed | -$239K | – | 389 |
|
|
2022
Q1 | $239K | Sell |
3,606
-912
| -20% | -$60.4K | 0.02% | 279 |
|
|
2021
Q4 | $263K | Buy |
4,518
+920
| +26% | +$53.6K | 0.02% | 246 |
|
|
2021
Q3 | $216K | Buy |
+3,598
| New | +$216K | 0.02% | 243 |
|
|
2018
Q4 | – | Sell |
-4,698
| Closed | -$186K | – | 127 |
|
|
2018
Q3 | $186K | Buy |
+4,698
| New | +$186K | 0.04% | 191 |
|
|
2018
Q2 | – | Sell |
-17,691
| Closed | -$302K | – | 501 |
|
|
2018
Q1 | $302K | Buy |
17,691
+1,371
| +8% | +$23.4K | 0.05% | 279 |
|
|
2017
Q4 | $578K | Buy |
+16,320
| New | +$578K | 0.07% | 208 |
|